Capillary posts consolidated net loss of ₹9.6 Cr on one-off ₹33.4 Cr fraud charge

Capillary Technologies' consolidated Q1 FY27 (quarter ended 30 June 2026) revenue rose 42.7% YoY and 34.1% QoQ to ₹256.64 Cr, lifted by SessionM's consolidation from 1 May 2026 alongside organic growth. Yet the group reported a consolidated net LOSS of ₹9.55 Cr, reversing a ₹43.36 Cr profit in Q4 FY26 and a marginal ₹0.75 Cr profit a year ago. The swing was driven entirely by a ₹33.39 Cr (€3.04 million) exceptional expense — a cyber-enabled banking fraud at SessionM Czech Republic s.r.o, the Czech step-down subsidiary acquired with SessionM, which saw unauthorised bank transfers during the quarter. Strip that out and pre-tax operating profit (before exceptional items) was ₹24.80 Cr, up 41.6% QoQ from ₹17.52 Cr and up sharply from a near-breakeven ₹0.55 Cr a year ago — underlying profitability improved even as the headline print shows red.

Adjusted net margin still compressed, to roughly 9.3% from ~21.9% in Q4 FY26 (per prior record), as employee costs jumped to ₹119.84 Cr (+33.8% QoQ) on SessionM integration and, per management's own pre-results commentary, routine annual salary increments; professional/consultancy and software & server costs also rose with the wider group perimeter. This tracks the prior guidance that FY27 margins would see near-term dilution from acquisition integration even as absolute EBITDA grows: profit before D&A/finance/exceptional items (₹46.01 Cr) rose 20.7% QoQ — absolute profitability up, percentage margin down, exactly the pattern flagged on the May 2026 concall. Management's claim that core (non-acquired) business margins continue to expand cannot be independently verified from the filing's single-segment P&L.

The stock went into the print at ₹532.35, up 3% over the past month of trading.

Forensic audit initiated (31 Jul 2026) into the banking fraud — ~₹4.67 Cr of diverted funds already frozen by banking authorities as recovery/insurance claims proceed.

On an annualised run-rate basis, the quarter's ₹256.64 Cr revenue tracks to roughly ₹1,026 Cr for FY27 — squarely inside management's guided ₹1,000-1,050 Cr band, so revenue guidance is on track. No formal Street consensus for this specific quarter was found in a web search; commentary on FY27 broadly expects 15-20% full-year PAT growth, a bar the fraud-hit reported number doesn't address but the ex-exceptional print is tracking toward. Standalone (the India entity alone, insulated from the Czech subsidiary loss) stayed solidly profitable at ₹7.77 Cr PAT — down from ₹9.90 Cr in Q4 FY26 but a turnaround from a ₹5.12 Cr loss a year ago — underscoring that the reported group loss is subsidiary-specific, not a standalone-business problem.